AU703327B2 - Agent for prevention or alleviation of allergy sypmtoms - Google Patents
Agent for prevention or alleviation of allergy sypmtoms Download PDFInfo
- Publication number
- AU703327B2 AU703327B2 AU17994/95A AU1799495A AU703327B2 AU 703327 B2 AU703327 B2 AU 703327B2 AU 17994/95 A AU17994/95 A AU 17994/95A AU 1799495 A AU1799495 A AU 1799495A AU 703327 B2 AU703327 B2 AU 703327B2
- Authority
- AU
- Australia
- Prior art keywords
- allergy
- alleviation
- prevention
- present
- derivative
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 206010020751 Hypersensitivity Diseases 0.000 title claims abstract description 57
- 208000026935 allergic disease Diseases 0.000 title claims abstract description 57
- 230000007815 allergy Effects 0.000 title claims abstract description 54
- 230000002265 prevention Effects 0.000 title claims abstract description 29
- 208000024891 symptom Diseases 0.000 claims abstract description 50
- 239000003963 antioxidant agent Substances 0.000 claims abstract description 37
- 230000003078 antioxidant effect Effects 0.000 claims abstract description 25
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 18
- XNWFXTOHNKPYMK-UHFFFAOYSA-N 3,3a,4,5,6,6a-hexahydrocyclopenta[c]dioxole Chemical class C1OOC2CCCC21 XNWFXTOHNKPYMK-UHFFFAOYSA-N 0.000 claims abstract description 12
- TVMXDCGIABBOFY-UHFFFAOYSA-N octane Chemical class CCCCCCCC TVMXDCGIABBOFY-UHFFFAOYSA-N 0.000 claims abstract description 11
- 125000000816 ethylene group Chemical group [H]C([H])([*:1])C([H])([H])[*:2] 0.000 claims abstract description 6
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 claims abstract description 6
- PEYUIKBAABKQKQ-AFHBHXEDSA-N (+)-sesamin Chemical compound C1=C2OCOC2=CC([C@H]2OC[C@H]3[C@@H]2CO[C@@H]3C2=CC=C3OCOC3=C2)=C1 PEYUIKBAABKQKQ-AFHBHXEDSA-N 0.000 claims description 54
- PEYUIKBAABKQKQ-UHFFFAOYSA-N epiasarinin Natural products C1=C2OCOC2=CC(C2OCC3C2COC3C2=CC=C3OCOC3=C2)=C1 PEYUIKBAABKQKQ-UHFFFAOYSA-N 0.000 claims description 54
- VRMHCMWQHAXTOR-CMOCDZPBSA-N sesamin Natural products C1=C2OCOC2=CC([C@@H]2OC[C@@]3(C)[C@H](C=4C=C5OCOC5=CC=4)OC[C@]32C)=C1 VRMHCMWQHAXTOR-CMOCDZPBSA-N 0.000 claims description 42
- 238000000034 method Methods 0.000 claims description 40
- -1 episesaminol Chemical compound 0.000 claims description 9
- 208000004262 Food Hypersensitivity Diseases 0.000 claims description 6
- 235000020932 food allergy Nutrition 0.000 claims description 6
- ZZMNWJVJUKMZJY-AFHBHXEDSA-N Sesamolin Chemical compound C1=C2OCOC2=CC([C@H]2OC[C@H]3[C@@H]2CO[C@@H]3OC2=CC=C3OCOC3=C2)=C1 ZZMNWJVJUKMZJY-AFHBHXEDSA-N 0.000 claims description 5
- ZZMNWJVJUKMZJY-UHFFFAOYSA-N Sesamolin Natural products C1=C2OCOC2=CC(C2OCC3C2COC3OC2=CC=C3OCOC3=C2)=C1 ZZMNWJVJUKMZJY-UHFFFAOYSA-N 0.000 claims description 5
- KQRXQIPRDKVZPW-ISZNXKAUSA-N sesaminol Chemical compound C1=C2OCOC2=CC([C@H]2OC[C@H]3[C@@H]2CO[C@@H]3C2=CC=3OCOC=3C=C2O)=C1 KQRXQIPRDKVZPW-ISZNXKAUSA-N 0.000 claims description 5
- KQRXQIPRDKVZPW-UHFFFAOYSA-N sesaminol Natural products C1=C2OCOC2=CC(C2OCC3C2COC3C2=CC=3OCOC=3C=C2O)=C1 KQRXQIPRDKVZPW-UHFFFAOYSA-N 0.000 claims description 5
- 206010016946 Food allergy Diseases 0.000 claims description 4
- HGXBRUKMWQGOIE-UHFFFAOYSA-N pinoresinol Chemical compound C1=C(O)C(OC)=CC(C2C3C(C(OC3)C=3C=C(OC)C(O)=CC=3)CO2)=C1 HGXBRUKMWQGOIE-UHFFFAOYSA-N 0.000 claims description 3
- 206010013700 Drug hypersensitivity Diseases 0.000 claims description 2
- 241000238631 Hexapoda Species 0.000 claims description 2
- 201000005311 drug allergy Diseases 0.000 claims description 2
- 125000000217 alkyl group Chemical group 0.000 abstract description 6
- 125000004432 carbon atom Chemical group C* 0.000 abstract description 5
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract description 5
- 235000013305 food Nutrition 0.000 description 38
- 235000006708 antioxidants Nutrition 0.000 description 34
- 239000000284 extract Substances 0.000 description 28
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 25
- 239000011732 tocopherol Substances 0.000 description 24
- 239000000203 mixture Substances 0.000 description 22
- 229930003799 tocopherol Natural products 0.000 description 19
- 229960001295 tocopherol Drugs 0.000 description 19
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 16
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 15
- GWNVDXQDILPJIG-NXOLIXFESA-N leukotriene C4 Chemical compound CCCCC\C=C/C\C=C/C=C/C=C/[C@H]([C@@H](O)CCCC(O)=O)SC[C@@H](C(=O)NCC(O)=O)NC(=O)CC[C@H](N)C(O)=O GWNVDXQDILPJIG-NXOLIXFESA-N 0.000 description 15
- 239000008159 sesame oil Substances 0.000 description 15
- 235000011803 sesame oil Nutrition 0.000 description 15
- 235000010384 tocopherol Nutrition 0.000 description 14
- GWNVDXQDILPJIG-SHSCPDMUSA-N Leukotriene C4 Natural products CCCCCC=C/CC=C/C=C/C=C/C(SCC(NC(=O)CCC(N)C(=O)O)C(=O)NCC(=O)O)C(O)CCCC(=O)O GWNVDXQDILPJIG-SHSCPDMUSA-N 0.000 description 13
- 241000207961 Sesamum Species 0.000 description 13
- 235000003434 Sesamum indicum Nutrition 0.000 description 13
- 239000000243 solution Substances 0.000 description 13
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 12
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 12
- 241000700159 Rattus Species 0.000 description 12
- 230000000694 effects Effects 0.000 description 12
- 210000004698 lymphocyte Anatomy 0.000 description 12
- 239000002904 solvent Substances 0.000 description 12
- 150000001875 compounds Chemical class 0.000 description 11
- 239000013566 allergen Substances 0.000 description 10
- 201000010105 allergic rhinitis Diseases 0.000 description 10
- 235000005911 diet Nutrition 0.000 description 10
- 230000037213 diet Effects 0.000 description 10
- 210000004072 lung Anatomy 0.000 description 10
- 238000004519 manufacturing process Methods 0.000 description 10
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 9
- 239000002775 capsule Substances 0.000 description 9
- 238000006243 chemical reaction Methods 0.000 description 9
- 238000002360 preparation method Methods 0.000 description 9
- 239000000126 substance Substances 0.000 description 9
- 239000012980 RPMI-1640 medium Substances 0.000 description 8
- 229930006000 Sucrose Natural products 0.000 description 8
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 8
- 210000004027 cell Anatomy 0.000 description 8
- 210000000952 spleen Anatomy 0.000 description 8
- 239000005720 sucrose Substances 0.000 description 8
- 201000008937 atopic dermatitis Diseases 0.000 description 7
- 206010012438 Dermatitis atopic Diseases 0.000 description 6
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 6
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 6
- 239000003925 fat Substances 0.000 description 6
- 235000019197 fats Nutrition 0.000 description 6
- 229960001340 histamine Drugs 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 125000002640 tocopherol group Chemical class 0.000 description 6
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 5
- 238000002965 ELISA Methods 0.000 description 5
- 241000196324 Embryophyta Species 0.000 description 5
- 206010039085 Rhinitis allergic Diseases 0.000 description 5
- 208000006673 asthma Diseases 0.000 description 5
- 230000037396 body weight Effects 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 239000012091 fetal bovine serum Substances 0.000 description 5
- 239000003921 oil Substances 0.000 description 5
- 235000019198 oils Nutrition 0.000 description 5
- 239000002953 phosphate buffered saline Substances 0.000 description 5
- 239000012487 rinsing solution Substances 0.000 description 5
- 230000002195 synergetic effect Effects 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- 235000019149 tocopherols Nutrition 0.000 description 5
- 229920002261 Corn starch Polymers 0.000 description 4
- 238000010171 animal model Methods 0.000 description 4
- 208000010668 atopic eczema Diseases 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 235000009508 confectionery Nutrition 0.000 description 4
- 239000008120 corn starch Substances 0.000 description 4
- 238000000605 extraction Methods 0.000 description 4
- 235000013376 functional food Nutrition 0.000 description 4
- 210000001165 lymph node Anatomy 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 238000002156 mixing Methods 0.000 description 4
- 235000021590 normal diet Nutrition 0.000 description 4
- 239000006228 supernatant Substances 0.000 description 4
- 239000003826 tablet Substances 0.000 description 4
- 229940088594 vitamin Drugs 0.000 description 4
- 229930003231 vitamin Natural products 0.000 description 4
- 239000011782 vitamin Substances 0.000 description 4
- 235000013343 vitamin Nutrition 0.000 description 4
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 description 3
- 241000251468 Actinopterygii Species 0.000 description 3
- 206010002198 Anaphylactic reaction Diseases 0.000 description 3
- ZAKOWWREFLAJOT-CEFNRUSXSA-N D-alpha-tocopherylacetate Chemical compound CC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-CEFNRUSXSA-N 0.000 description 3
- 239000004470 DL Methionine Substances 0.000 description 3
- 108060003951 Immunoglobulin Proteins 0.000 description 3
- 230000036783 anaphylactic response Effects 0.000 description 3
- 208000003455 anaphylaxis Diseases 0.000 description 3
- 230000003266 anti-allergic effect Effects 0.000 description 3
- 210000000702 aorta abdominal Anatomy 0.000 description 3
- 235000014121 butter Nutrition 0.000 description 3
- 239000005018 casein Substances 0.000 description 3
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 3
- 235000021240 caseins Nutrition 0.000 description 3
- 239000006285 cell suspension Substances 0.000 description 3
- 239000001913 cellulose Substances 0.000 description 3
- 235000010980 cellulose Nutrition 0.000 description 3
- 229920002678 cellulose Polymers 0.000 description 3
- 238000005119 centrifugation Methods 0.000 description 3
- 229960004874 choline bitartrate Drugs 0.000 description 3
- QWJSAWXRUVVRLH-UHFFFAOYSA-M choline bitartrate Chemical compound C[N+](C)(C)CCO.OC(=O)C(O)C(O)C([O-])=O QWJSAWXRUVVRLH-UHFFFAOYSA-M 0.000 description 3
- 239000002285 corn oil Substances 0.000 description 3
- 235000005687 corn oil Nutrition 0.000 description 3
- 239000012228 culture supernatant Substances 0.000 description 3
- 235000021186 dishes Nutrition 0.000 description 3
- 238000000684 flow cytometry Methods 0.000 description 3
- 235000013402 health food Nutrition 0.000 description 3
- 102000018358 immunoglobulin Human genes 0.000 description 3
- 208000030603 inherited susceptibility to asthma Diseases 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 229910052500 inorganic mineral Inorganic materials 0.000 description 3
- 150000002617 leukotrienes Chemical class 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- FFEARJCKVFRZRR-UHFFFAOYSA-N methionine Chemical compound CSCCC(N)C(O)=O FFEARJCKVFRZRR-UHFFFAOYSA-N 0.000 description 3
- 229930182817 methionine Natural products 0.000 description 3
- 235000006109 methionine Nutrition 0.000 description 3
- 239000011707 mineral Substances 0.000 description 3
- 235000010755 mineral Nutrition 0.000 description 3
- 239000002736 nonionic surfactant Substances 0.000 description 3
- 235000016709 nutrition Nutrition 0.000 description 3
- 210000002381 plasma Anatomy 0.000 description 3
- 239000003755 preservative agent Substances 0.000 description 3
- 235000018102 proteins Nutrition 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- 229940042585 tocopherol acetate Drugs 0.000 description 3
- 150000003722 vitamin derivatives Chemical class 0.000 description 3
- 206010002091 Anaesthesia Diseases 0.000 description 2
- NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 description 2
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 2
- 201000004624 Dermatitis Diseases 0.000 description 2
- 206010014824 Endotoxic shock Diseases 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 244000068988 Glycine max Species 0.000 description 2
- 235000010469 Glycine max Nutrition 0.000 description 2
- 239000004472 Lysine Substances 0.000 description 2
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 2
- 201000004681 Psoriasis Diseases 0.000 description 2
- 206010040070 Septic Shock Diseases 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- BGNXCDMCOKJUMV-UHFFFAOYSA-N Tert-Butylhydroquinone Chemical compound CC(C)(C)C1=CC(O)=CC=C1O BGNXCDMCOKJUMV-UHFFFAOYSA-N 0.000 description 2
- 244000299461 Theobroma cacao Species 0.000 description 2
- 208000024780 Urticaria Diseases 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 235000013334 alcoholic beverage Nutrition 0.000 description 2
- 235000001014 amino acid Nutrition 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 230000037005 anaesthesia Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- CZBZUDVBLSSABA-UHFFFAOYSA-N butylated hydroxyanisole Chemical compound COC1=CC=C(O)C(C(C)(C)C)=C1.COC1=CC=C(O)C=C1C(C)(C)C CZBZUDVBLSSABA-UHFFFAOYSA-N 0.000 description 2
- FDSDTBUPSURDBL-LOFNIBRQSA-N canthaxanthin Chemical compound CC=1C(=O)CCC(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)C(=O)CCC1(C)C FDSDTBUPSURDBL-LOFNIBRQSA-N 0.000 description 2
- 235000021466 carotenoid Nutrition 0.000 description 2
- 150000001747 carotenoids Chemical class 0.000 description 2
- 235000019219 chocolate Nutrition 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- QBKSWRVVCFFDOT-UHFFFAOYSA-N gossypol Chemical compound CC(C)C1=C(O)C(O)=C(C=O)C2=C(O)C(C=3C(O)=C4C(C=O)=C(O)C(O)=C(C4=CC=3C)C(C)C)=C(C)C=C21 QBKSWRVVCFFDOT-UHFFFAOYSA-N 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- LHGVFZTZFXWLCP-UHFFFAOYSA-N guaiacol Chemical compound COC1=CC=CC=C1O LHGVFZTZFXWLCP-UHFFFAOYSA-N 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 210000002443 helper t lymphocyte Anatomy 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 210000003630 histaminocyte Anatomy 0.000 description 2
- 230000036046 immunoreaction Effects 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 208000023589 ischemic disease Diseases 0.000 description 2
- VNYSSYRCGWBHLG-AMOLWHMGSA-M leukotriene B4(1-) Chemical compound CCCCC\C=C/C[C@@H](O)\C=C\C=C\C=C/[C@@H](O)CCCC([O-])=O VNYSSYRCGWBHLG-AMOLWHMGSA-M 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 235000021056 liquid food Nutrition 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 238000012423 maintenance Methods 0.000 description 2
- HCZKYJDFEPMADG-TXEJJXNPSA-N masoprocol Chemical compound C([C@H](C)[C@H](C)CC=1C=C(O)C(O)=CC=1)C1=CC=C(O)C(O)=C1 HCZKYJDFEPMADG-TXEJJXNPSA-N 0.000 description 2
- 210000004400 mucous membrane Anatomy 0.000 description 2
- 239000005445 natural material Substances 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 230000035764 nutrition Effects 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- FDPIMTJIUBPUKL-UHFFFAOYSA-N pentan-3-one Chemical compound CCC(=O)CC FDPIMTJIUBPUKL-UHFFFAOYSA-N 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 238000003127 radioimmunoassay Methods 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 235000013599 spices Nutrition 0.000 description 2
- 238000012453 sprague-dawley rat model Methods 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- HGXBRUKMWQGOIE-AFHBHXEDSA-N (+)-pinoresinol Chemical compound C1=C(O)C(OC)=CC([C@@H]2[C@@H]3[C@@H]([C@H](OC3)C=3C=C(OC)C(O)=CC=3)CO2)=C1 HGXBRUKMWQGOIE-AFHBHXEDSA-N 0.000 description 1
- ZORQXIQZAOLNGE-UHFFFAOYSA-N 1,1-difluorocyclohexane Chemical compound FC1(F)CCCCC1 ZORQXIQZAOLNGE-UHFFFAOYSA-N 0.000 description 1
- QCVGEOXPDFCNHA-UHFFFAOYSA-N 5,5-dimethyl-2,4-dioxo-1,3-oxazolidine-3-carboxamide Chemical compound CC1(C)OC(=O)N(C(N)=O)C1=O QCVGEOXPDFCNHA-UHFFFAOYSA-N 0.000 description 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- 244000167222 Acanthopanax sessiliflorus Species 0.000 description 1
- 235000017615 Acanthopanax sessiliflorus Nutrition 0.000 description 1
- 239000000275 Adrenocorticotropic Hormone Substances 0.000 description 1
- 244000105624 Arachis hypogaea Species 0.000 description 1
- 241001472196 Asarum heterotropoides Species 0.000 description 1
- 241001289295 Asarum sieboldii Species 0.000 description 1
- JEBFVOLFMLUKLF-IFPLVEIFSA-N Astaxanthin Natural products CC(=C/C=C/C(=C/C=C/C1=C(C)C(=O)C(O)CC1(C)C)/C)C=CC=C(/C)C=CC=C(/C)C=CC2=C(C)C(=O)C(O)CC2(C)C JEBFVOLFMLUKLF-IFPLVEIFSA-N 0.000 description 1
- 208000012657 Atopic disease Diseases 0.000 description 1
- 235000011960 Brassica ruvo Nutrition 0.000 description 1
- 210000001266 CD8-positive T-lymphocyte Anatomy 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 229940126062 Compound A Drugs 0.000 description 1
- 102400000739 Corticotropin Human genes 0.000 description 1
- 101800000414 Corticotropin Proteins 0.000 description 1
- 206010012434 Dermatitis allergic Diseases 0.000 description 1
- 206010012442 Dermatitis contact Diseases 0.000 description 1
- 206010048768 Dermatosis Diseases 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 108010000912 Egg Proteins Proteins 0.000 description 1
- 102000002322 Egg Proteins Human genes 0.000 description 1
- 241000092728 Eleutherococcus gracilistylus Species 0.000 description 1
- 241001632410 Eleutherococcus senticosus Species 0.000 description 1
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 1
- UIOFUWFRIANQPC-JKIFEVAISA-N Floxacillin Chemical compound N([C@@H]1C(N2[C@H](C(C)(C)S[C@@H]21)C(O)=O)=O)C(=O)C1=C(C)ON=C1C1=C(F)C=CC=C1Cl UIOFUWFRIANQPC-JKIFEVAISA-N 0.000 description 1
- ACYXDIZTQDLTCB-UVIKLTKHSA-N Fukinolic acid Chemical compound O([C@H](C(=O)O)[C@](O)(CC=1C=C(O)C(O)=CC=1)C(O)=O)C(=O)\C=C\C1=CC=C(O)C(O)=C1 ACYXDIZTQDLTCB-UVIKLTKHSA-N 0.000 description 1
- 244000194101 Ginkgo biloba Species 0.000 description 1
- 235000008100 Ginkgo biloba Nutrition 0.000 description 1
- 239000004263 Guaiac resin Substances 0.000 description 1
- 229920000932 Gum guaicum Polymers 0.000 description 1
- NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- 206010022998 Irritability Diseases 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 239000004166 Lanolin Substances 0.000 description 1
- 235000019510 Long pepper Nutrition 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 208000019695 Migraine disease Diseases 0.000 description 1
- 108010011756 Milk Proteins Proteins 0.000 description 1
- 102000014171 Milk Proteins Human genes 0.000 description 1
- 244000294411 Mirabilis expansa Species 0.000 description 1
- 235000015429 Mirabilis expansa Nutrition 0.000 description 1
- YBHQCJILTOVLHD-YVMONPNESA-N Mirin Chemical compound S1C(N)=NC(=O)\C1=C\C1=CC=C(O)C=C1 YBHQCJILTOVLHD-YVMONPNESA-N 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 108010038807 Oligopeptides Proteins 0.000 description 1
- 102000015636 Oligopeptides Human genes 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 108010058846 Ovalbumin Proteins 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 241001629585 Paulownia fortunei Species 0.000 description 1
- 240000002834 Paulownia tomentosa Species 0.000 description 1
- 235000010678 Paulownia tomentosa Nutrition 0.000 description 1
- OOUTWVMJGMVRQF-DOYZGLONSA-N Phoenicoxanthin Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)C(=O)C(O)CC1(C)C)C=CC=C(/C)C=CC2=C(C)C(=O)CCC2(C)C OOUTWVMJGMVRQF-DOYZGLONSA-N 0.000 description 1
- 240000003455 Piper longum Species 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 229920001214 Polysorbate 60 Polymers 0.000 description 1
- 108010009736 Protein Hydrolysates Proteins 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 1
- 101100545004 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) YSP2 gene Proteins 0.000 description 1
- LUSZGTFNYDARNI-UHFFFAOYSA-N Sesamol Natural products OC1=CC=C2OCOC2=C1 LUSZGTFNYDARNI-UHFFFAOYSA-N 0.000 description 1
- 108010073771 Soybean Proteins Proteins 0.000 description 1
- 229930182558 Sterol Natural products 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- QHOPXUFELLHKAS-UHFFFAOYSA-N Thespesin Natural products CC(C)c1c(O)c(O)c2C(O)Oc3c(c(C)cc1c23)-c1c2OC(O)c3c(O)c(O)c(C(C)C)c(cc1C)c23 QHOPXUFELLHKAS-UHFFFAOYSA-N 0.000 description 1
- 241000990222 Tometes Species 0.000 description 1
- 235000021307 Triticum Nutrition 0.000 description 1
- 241000209140 Triticum Species 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- VBIRCRCPHNUJAS-UHFFFAOYSA-N Xanthoxylol Chemical compound C1=C(O)C(OC)=CC(C2C3C(C(OC3)C=3C=C4OCOC4=CC=3)CO2)=C1 VBIRCRCPHNUJAS-UHFFFAOYSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 238000003811 acetone extraction Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 201000009961 allergic asthma Diseases 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 229940124623 antihistamine drug Drugs 0.000 description 1
- 235000013793 astaxanthin Nutrition 0.000 description 1
- 239000001168 astaxanthin Substances 0.000 description 1
- MQZIGYBFDRPAKN-ZWAPEEGVSA-N astaxanthin Chemical compound C([C@H](O)C(=O)C=1C)C(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)C(=O)[C@@H](O)CC1(C)C MQZIGYBFDRPAKN-ZWAPEEGVSA-N 0.000 description 1
- 229940022405 astaxanthin Drugs 0.000 description 1
- 125000004429 atom Chemical group 0.000 description 1
- 208000010216 atopic IgE responsiveness Diseases 0.000 description 1
- OHDRQQURAXLVGJ-HLVWOLMTSA-N azane;(2e)-3-ethyl-2-[(e)-(3-ethyl-6-sulfo-1,3-benzothiazol-2-ylidene)hydrazinylidene]-1,3-benzothiazole-6-sulfonic acid Chemical compound [NH4+].[NH4+].S/1C2=CC(S([O-])(=O)=O)=CC=C2N(CC)C\1=N/N=C1/SC2=CC(S([O-])(=O)=O)=CC=C2N1CC OHDRQQURAXLVGJ-HLVWOLMTSA-N 0.000 description 1
- 235000015241 bacon Nutrition 0.000 description 1
- 235000013527 bean curd Nutrition 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 235000015895 biscuits Nutrition 0.000 description 1
- 239000002981 blocking agent Substances 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 235000008429 bread Nutrition 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 235000015155 buttermilk Nutrition 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 235000012970 cakes Nutrition 0.000 description 1
- 235000012682 canthaxanthin Nutrition 0.000 description 1
- 239000001659 canthaxanthin Substances 0.000 description 1
- 229940008033 canthaxanthin Drugs 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 150000001765 catechin Chemical class 0.000 description 1
- ADRVNXBAWSRFAJ-UHFFFAOYSA-N catechin Natural products OC1Cc2cc(O)cc(O)c2OC1c3ccc(O)c(O)c3 ADRVNXBAWSRFAJ-UHFFFAOYSA-N 0.000 description 1
- 235000005487 catechin Nutrition 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 239000007979 citrate buffer Substances 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- JNGZXGGOCLZBFB-IVCQMTBJSA-N compound E Chemical compound N([C@@H](C)C(=O)N[C@@H]1C(N(C)C2=CC=CC=C2C(C=2C=CC=CC=2)=N1)=O)C(=O)CC1=CC(F)=CC(F)=C1 JNGZXGGOCLZBFB-IVCQMTBJSA-N 0.000 description 1
- 208000010247 contact dermatitis Diseases 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- IDLFZVILOHSSID-OVLDLUHVSA-N corticotropin Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)NC(=O)[C@@H](N)CO)C1=CC=C(O)C=C1 IDLFZVILOHSSID-OVLDLUHVSA-N 0.000 description 1
- 229960000258 corticotropin Drugs 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- XEYBRNLFEZDVAW-ARSRFYASSA-N dinoprostone Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O XEYBRNLFEZDVAW-ARSRFYASSA-N 0.000 description 1
- 229960002986 dinoprostone Drugs 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 235000015071 dressings Nutrition 0.000 description 1
- 229940126534 drug product Drugs 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 239000003221 ear drop Substances 0.000 description 1
- 229940047652 ear drops Drugs 0.000 description 1
- 235000014103 egg white Nutrition 0.000 description 1
- 210000000969 egg white Anatomy 0.000 description 1
- 235000013601 eggs Nutrition 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 239000002662 enteric coated tablet Substances 0.000 description 1
- HCZKYJDFEPMADG-UHFFFAOYSA-N erythro-nordihydroguaiaretic acid Natural products C=1C=C(O)C(O)=CC=1CC(C)C(C)CC1=CC=C(O)C(O)=C1 HCZKYJDFEPMADG-UHFFFAOYSA-N 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 239000003889 eye drop Substances 0.000 description 1
- 229940012356 eye drops Drugs 0.000 description 1
- 235000021107 fermented food Nutrition 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 150000002212 flavone derivatives Chemical class 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 235000013312 flour Nutrition 0.000 description 1
- 235000013373 food additive Nutrition 0.000 description 1
- 239000002778 food additive Substances 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- ACYXDIZTQDLTCB-YLJYHZDGSA-N fukinolic acid Natural products OC(=O)[C@@H](OC(=O)C=Cc1ccc(O)c(O)c1)[C@](O)(Cc2ccc(O)c(O)c2)C(=O)O ACYXDIZTQDLTCB-YLJYHZDGSA-N 0.000 description 1
- LNTHITQWFMADLM-UHFFFAOYSA-N gallic acid Chemical class OC(=O)C1=CC(O)=C(O)C(O)=C1 LNTHITQWFMADLM-UHFFFAOYSA-N 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 229930000755 gossypol Natural products 0.000 description 1
- 229950005277 gossypol Drugs 0.000 description 1
- 235000019278 guaiac resin Nutrition 0.000 description 1
- 229960001867 guaiacol Drugs 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 230000007803 itching Effects 0.000 description 1
- 238000004898 kneading Methods 0.000 description 1
- BEJNERDRQOWKJM-UHFFFAOYSA-N kojic acid Chemical compound OCC1=CC(=O)C(O)=CO1 BEJNERDRQOWKJM-UHFFFAOYSA-N 0.000 description 1
- 229960004705 kojic acid Drugs 0.000 description 1
- WZNJWVWKTVETCG-UHFFFAOYSA-N kojic acid Natural products OC(=O)C(N)CN1C=CC(=O)C(O)=C1 WZNJWVWKTVETCG-UHFFFAOYSA-N 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 229940039717 lanolin Drugs 0.000 description 1
- 235000019388 lanolin Nutrition 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 229960003511 macrogol Drugs 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 235000013310 margarine Nutrition 0.000 description 1
- 239000003264 margarine Substances 0.000 description 1
- 229960003951 masoprocol Drugs 0.000 description 1
- 239000008268 mayonnaise Substances 0.000 description 1
- 235000010746 mayonnaise Nutrition 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 230000027939 micturition Effects 0.000 description 1
- 206010027599 migraine Diseases 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 235000021239 milk protein Nutrition 0.000 description 1
- 235000013536 miso Nutrition 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 238000000465 moulding Methods 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 239000007923 nasal drop Substances 0.000 description 1
- 229940100662 nasal drops Drugs 0.000 description 1
- 210000002850 nasal mucosa Anatomy 0.000 description 1
- 230000000422 nocturnal effect Effects 0.000 description 1
- 235000012149 noodles Nutrition 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 210000004798 organs belonging to the digestive system Anatomy 0.000 description 1
- 235000019449 other food additives Nutrition 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 235000020232 peanut Nutrition 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- OHOPKHNWLCMLSW-UHFFFAOYSA-N pinoresinol Natural products C1=C(O)C(OC)=CC(C2C3C(C(OC3)C=3C=C(CO)C(O)=CC=3)CO2)=C1 OHOPKHNWLCMLSW-UHFFFAOYSA-N 0.000 description 1
- 235000007221 pinoresinol Nutrition 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- XEYBRNLFEZDVAW-UHFFFAOYSA-N prostaglandin E2 Natural products CCCCCC(O)C=CC1C(O)CC(=O)C1CC=CCCCC(O)=O XEYBRNLFEZDVAW-UHFFFAOYSA-N 0.000 description 1
- 210000001147 pulmonary artery Anatomy 0.000 description 1
- 239000012264 purified product Substances 0.000 description 1
- 150000003216 pyrazines Chemical class 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 235000013580 sausages Nutrition 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 235000019615 sensations Nutrition 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 229940059463 sesame seed extract Drugs 0.000 description 1
- OJVGWDJIYBTWDS-UHFFFAOYSA-N sesamolinol Chemical compound C1=C(O)C(OC)=CC(OC2C3C(C(OC3)C=3C=C4OCOC4=CC=3)CO2)=C1 OJVGWDJIYBTWDS-UHFFFAOYSA-N 0.000 description 1
- 238000004904 shortening Methods 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 210000002460 smooth muscle Anatomy 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 235000014214 soft drink Nutrition 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 235000021055 solid food Nutrition 0.000 description 1
- 235000011069 sorbitan monooleate Nutrition 0.000 description 1
- 239000001593 sorbitan monooleate Substances 0.000 description 1
- 229940035049 sorbitan monooleate Drugs 0.000 description 1
- 235000013555 soy sauce Nutrition 0.000 description 1
- 235000019710 soybean protein Nutrition 0.000 description 1
- 235000011496 sports drink Nutrition 0.000 description 1
- 239000012086 standard solution Substances 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 235000003702 sterols Nutrition 0.000 description 1
- 150000003432 sterols Chemical class 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- KOWMJRJXZMEZLD-UHFFFAOYSA-N syringaresinol Chemical compound COC1=C(O)C(OC)=CC(C2C3C(C(OC3)C=3C=C(OC)C(O)=C(OC)C=3)CO2)=C1 KOWMJRJXZMEZLD-UHFFFAOYSA-N 0.000 description 1
- LVUPFEOCDSHRBL-UHFFFAOYSA-N syringaresinol Natural products COc1cccc(OC)c1C2OCC3C2COC3c4c(OC)cccc4OC LVUPFEOCDSHRBL-UHFFFAOYSA-N 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 235000013616 tea Nutrition 0.000 description 1
- 150000003505 terpenes Chemical class 0.000 description 1
- 235000007586 terpenes Nutrition 0.000 description 1
- 239000004250 tert-Butylhydroquinone Substances 0.000 description 1
- 235000019281 tert-butylhydroquinone Nutrition 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 150000003611 tocopherol derivatives Chemical class 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- 235000021404 traditional food Nutrition 0.000 description 1
- 230000002485 urinary effect Effects 0.000 description 1
- 230000036318 urination frequency Effects 0.000 description 1
- 229940099259 vaseline Drugs 0.000 description 1
- 235000021419 vinegar Nutrition 0.000 description 1
- 239000000052 vinegar Substances 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 239000010497 wheat germ oil Substances 0.000 description 1
- BURBOJZOZGMMQF-UHFFFAOYSA-N xanthoxylol Natural products C1=C(O)C(OC)=CC=C1C1C(COC2C=3C=C4OCOC4=CC=3)C2CO1 BURBOJZOZGMMQF-UHFFFAOYSA-N 0.000 description 1
- 235000013618 yogurt Nutrition 0.000 description 1
- FGYKUFVNYVMTAM-NTZRDTQNSA-N ε-tocopherol Chemical compound OC1=CC(C)=C2OC(CC/C=C(C)/CC/C=C(C)/CCC=C(C)C)(C)CCC2=C1C FGYKUFVNYVMTAM-NTZRDTQNSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
- A23L29/03—Organic compounds
- A23L29/035—Organic compounds containing oxygen as heteroatom
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/304—Foods, ingredients or supplements having a functional effect on health having a modulation effect on allergy and risk of allergy
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/20—Natural extracts
- A23V2250/21—Plant extracts
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Nutrition Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Toxicology (AREA)
- Botany (AREA)
- Mycology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
An agent for the prevention or alleviation of allergy symptoms contains as an effective component a dioxabycyclo[3.3.0]octane derivative represented by the following general formula (I): <CHEM> where R<1>, R<2>, R<3>, R<4>, R<5> and R<6> each independently represent a hydrogen atom or alkyl group of 1-3 carbon atoms, or R<1> and R<2> and/or R<4> and R<5> together represent a methylene or ethylene group, and n, m and 1 represent 0 or 1. An agent for the prevention or alleviation of allergy symptoms also contains as an effective component an antioxidant in addition to the dioxabicyclo[3.3.0]octane derivative.
Description
STY-C175 AGENT FOR PREVENTION OR ALLEVIATION OF ALLERGY
SYMPTOMS
BACKGROUND OF INVENTION 1. Field of Invention The present invention relates to an agent for the prevention or alleviation of allergy symptoms comprising as an effective component a dioxabycyclo[3.3.0]octane derivative, to a food product with an effect of preventing or alleviating allergy symptoms comprising a dioxabycyclo[3.3.0]octane derivative or an extract whose main component is said derivative, and to a method for producing the same.
The present invention also relates to an agent for the prevention or alleviation of allergy symptoms comprising as effective components a dioxabycyclo[3.3.0]octane derivative and an antioxidant, to a food product with an effect of preventing or alleviating allergy symptoms comprising both a dioxabycyclo[3.3.0]octane derivative or an extract whose main component is said derivative and an antioxidant, and to a method for producing the same.
2. Related Art Allergic asthma, allergic rhinitis, atopic disorders and the like are believed to occur due to interference on biological tissue with the various chemical mediators released from the lungs and other organs, causing contraction of smooth muscle such as bronchial muscle and pulmonary vessels and excessive permeability of epithelial vessels. Of these chemical mediators, the most noted are histamine and SRS-A (slowreacting release substance of anaphylaxis). In recent years, SRS-A itself has been identified as the peptide leukotrienes
C
4 D, and E 4
(LTC
4
LTD
4
LTE
4 and the multifarious physiological effects and pathologic connections of these leukotrienes have been widely 2 studied.
Furthermore, SRS-A has been implicated in relation to bronchial asthma, allergic rhinitis and dermatitis, atopic dermatitis, and even ischemic diseases such as myocardial infarction, and cardial anaphylaxis, endotoxic shock, psoriasis, and the like. Consequently, much attention has been directed to the development of agents which suppress production of or act against
SRS-A.
In addition, with the recent increase in the number of patients with allergy symptoms such as atopic dermatitis and pollenosis, their treatment has become a matter of public concern.
However, at present it is most common to rely on symptomatic therapies, and despite the strong desire for a superior curing agent to thoroughly cure allergy symptoms, it must be said that development thereof is still far out of reach. Recently, a number of different antihistamine drugs and agents which inhibit the production of or act against SRS-A have been developed, but they are still inadequate from the point of view of side effects. Other inhibitors which are used include adrenocorticotropic hormone agents, but these often cause serious side effects in patients and thus should not be widely used as drugs.
SUMMARY OF INVENTION Consequently, the present invention is aimed at providing a novel agent for the prevention or alleviation :of allergy symptoms which has high stability and few side Seffects, as well as a food product with an effect of preventing or alleviating allergy symptoms and a method :of producing the same.
We the present inventors have carried out much research for the purpose of achieving the above-mentioned objects, and as a result have found that dioxabicyclo[3.0.0]octane derivatives isolated from sesame seeds, sesame lees or sesame oil, or obtained by synthesis, are effective for preventing or alleviating 3 allergy symptoms, and that the combined use of the derivatives with antioxidants is also effective for preventing or alleviating allergy symptoms, and the present invention has thus been completed.
That is, the present invention provides agents for the prevention or alleviation of allergy symptoms comprising as an effective component a dioxabycyclo[3.3.0]octane derivative represented by the following general formula R1O OR 2 S(0)
OR^
O
is (R30)m
R
5 s (OR 6 I 3 4 3 6 where R, R R, R, R, R and R each independently represent a hydrogen atom or alkyl group of 1 to 3 carbon 20 atoms, or R and R 2 and/or R4 and R 5 together represent a methylene or ethylene group, and n, m and I represent 0 or 1.
The present invention also provides food products which have an effect of preventing or alleviating allergy symptoms, which are prepared with addition of the abovementioned derivatives or extracts containing them as main components.
Furthermore, it provides foods with an effect of preventing or alleviating allergy symptoms which are characterized by being prepared with the addition of the above-mentioned derivatives or of extracts containing them as main components, to foods which substantially contain no such derivatives, as well as a method of producing the same.
The present invention further provides agents for the prevention or alleviation of allergy symptoms 4 comprising as effective components an antioxidant in addition to a dioxabicyclo[3.3.0Joctane derivative represented by the following general formula
R
1 0 OR 2 0 (0)n
OR
4 RO
(R
6 2 where R R R P and R 6 each independently represent a hydrogen atom or alkyl group of I to 3 carbon atoms, or R and R and/or R' and R together represent a methylene or ethylene group, and n, m and 1 represent 0 or 1.
The present invention further provides food products with an effect of preventing or alleviating allergy symptoms, which are prepared with the addition of antioxidants with the above-mentioned dioxabicyclo[3.3.0]octane derivatives or extracts whose main components are those derivatives.
In addition, the present invention provides food products with an effect of preventing or alleviating 25 allergy symptoms, which are characterized by being prepared with the addition of the above-mentioned derivatives or of extracts containing them as main components and of antioxidants, to foods which substantially contain no such derivatives, as well as a method of producing the same.
BRIEF DESCRIPTION OF THE DRAWINGS Fig. 1 is a graph showing the difference in lung tissue LTC, concentrations of male BN rats given diets containing sesamin and/or tocopherol.
Fig. 2 is a group of graphs showing the serum immunoglobulin IgA, IgE, IgG and 1gM concentrations of 5 male BN rats given diets containing sesamin and/or tocopherol.
Fig. 3 is a group of graphs showing the differences in spleen tissue LTB concentrations, lung tissue LTC 4 concentrations and blood plasma histamine concentrations of male SD rats given diets containing sesamin and/or tocopherol.
DETAILED DESCRIPTION The dioxabicyclo[3.3.0]octane derivatives which are the effective components according to the present invention are compounds represented by the following general formula (I1:
R
1 O OR 2 OR 4 (OOn (0) n 3 0)m
(OR
6 2 1 2 3 4 6 20 where R R R R R and R 6 each independently represent a hydrogen atom or alkyl group of 1 to 3 carbon atoms, or RI and R z and/or R4 and R 5 together represent a methylene or ethylene group, and n, m and 1 represent 0 or 1; and here, the alkyl group of 1 to 3 carbon atoms S* 25 may be methyl, ethyl, n-propyl or isopropyl group, or the like.
More concrete examples of the compounds include sesamin, sesaminol, episesamin, episesaminol, sesamolin, 2-(3,4-methylenedioxyphenyl)-6-(3-methoxy-4hydroxyphenyl)-3,7-dioxabicyclo[3.3.0]octane, 2,6-bis-(3methoxy-4-hydroxyphenyl)-3,7-dioxabicyclo(3.3.0]octane and 2-(3,4-methylenedioxyphenyl)-6-(3-methoxy-4hydroxyphenoxy)-3,7-dioxabicyclo[3.3.0]octane.
Enantiomers of the above-mentioned compounds are also within the scope of the present invention.
6 According to the present invention, the abovementioned dioxabicyclo[3.3.0]octane derivatives (hereunder, "the derivatives of the present invention") are used alone or two or more thereof are used combination. Furthermore, the derivatives of the present invention are not limited to high purity products, as there may also be used extracts consisting mainly of one or more of the above-mentioned dioxabicyclo[3.3.0]octane derivatives.
An extract containing a derivative of the present invention as a main component may be prepared by extraction by a normal method from a natural substance containing the derivative of the present invention.
Natural substances containing derivatives of the present invention include sesame oil, sesame lees, sesame oil byproducts, sesame seeds, Gokahi derived from a medicinal plant which is Acanthopanax gracilistylus W.W. Smith or Acanthopanax sessiliflorus Seem, or Acanthopanax senticosus Harms or Acanthopanax henryi Harms or Acanthopanax verticillatus Hoo; Toboku derived from a medicinal plant which is Paulownia fortunei Hewsl or Paulownia tomentosa; Hakukajuhi derived frow a medicinal plant which is Ginkgo biloba Hihatsu derived from a medicinal plant which is Piper longum Saishin 25 (Asiasari radix) derived from a medicinal plant which is S" Asarum heterotropoides F. Schm. var. mandshuricum Kitag.
*or Asarum sieboldii Mig.; etc.
The content of the derivative of the present invention in an extract containing it as a main component 30 is 0.1 wt% or greater, preferably 1.0 wt% or greater, and more preferably 5.0 wt% or greater, and particularly in the case of sesamin and episesamin, the combined content is 0.05 wt% or greater, preferably 0.5 wt% or greater, and more preferably 2.0 wt% or greater.
S 35 For example, to obtain an extract consisting mainly of a derivative of the present invention from sesame oil, the extraction and concentration may be done using any of -7 a variety of organic solvents (such as acetone, methyl ethyl ketone, diethyl ketone, methanol, ethanol, etc.) which are substantially immiscible with sesame oil and are able to extract and dissolve the derivative of the present invention.
An example thereof is a method in which sesame oil is uniformly mixed with one of the above-mentioned solvents and then allowed to stand at a low temperature, the phases are separated by a usual method such as centrifugation, and the solvent is then evaporated off from the solvent fraction; more specifically, sesame oil is dissolved in a 2 to 10 fold amount, and preferably a 6 to 8 fold amount of acetone, allowed to stand overnight at -80 0 C during which time the oil component precipitates, and acetone is distilled off from the filtrate obtained by filtration to obtain an extract containing a derivative of the present invention as a main component thereof.
Another example is a method in which sesame oil is mixed with hot methanol or hot ethanol and allowed to stand at room temperature, and the solvent is evaporated off from the solvent fraction; more specifically, sesame oil is vigorously mixed in a 2 to 10 fold amount, and preferably a 5 to 7 fold amount of hot methanol (50WC or higher) or hot ethanol (50*C or higher), after which the mixture is allowed to stand at room temperature or the phases are separated by a usual method such as centrifugation, and the solvent is distilled off from the solvent fraction to obtain an extract containing a derivative of the present invention as a main component ~:thereof.
In addition, a supercritical gas extract may also be used to obtain an extract containing a derivative of the ****present invention as a main component thereof.
The sesame oil used may be a purified product or any crude product prior to the decoloring step of the production process for sesame oil.
8 In order to obtain an extract consisting mainly of a derivative of the present invention from sesame seeds or sesame lees (defatted sesame seeds, residual oil: 8 to the sesame seeds or sesame lees may be crushed if necessary and then extracted by a usual method using a desired solvent, for example any of the above-mentioned solvents which are used for extraction from sesame oil.
After separating off the extract residue, the solvent may be removed from the extract solution by evaporation, etc.
to obtain the extract.
The object compound of the derivative of the present invention may be isolated from sesame oil extract, sesame lees extract or sesame seed extract prepared by the methods mentioned above, by treatment according to a usual method such as column chromatography, high performance liquid chromatography, recrystallization, distillation, liquid-liquid exchange distribution chromatography, or the like. More specifically, a derivative of the present invention such as sesamin, episesamin, sesaminol, episesaminol, sesamolin, 2-(3,4methylenedioxyphenyl)-6-( 3 -methoxy-4-hydroxyphenyl)-3,7dioxabicyclo[3.
3 .0]octane, 2 ,6-bis-(3-methoxy-4hydroxyphenyl)-3,7-dioxabicyclo[3.3.0octane or 2-(3,4methylenedioxyphenyl)-6-( 3 -methoxy-4-hydroxyphenoxy)-3,7- 25 dioxabicyclo[3.3.0]octane may be obtained by using methanol/water (60:40) in an eluent in a reverse phase column (5C 18 separating off the above-mentioned extract by high performance liquid chromatography and distilling :'off the solvent, and then recrystallizing the obtained crystals with ethanol. The methods of obtaining and purifying derivatives of the present invention and extracts containing them as main components are not limited to these.
A derivative of the present invention may also be 35 obtained by synthesis according to a usual method.
For example, sesamin and episesamin may be 9synthesized by the method of Beroza, et al. Am. Chem.
Soc. 7, 1242 (1956)], while pinoresinol (where R'-R4H, 235 R =R CH 3 and n-m=1-0 in the general formula may be synthesized by the method of Freundenberg, et al. [Chem.
Ber., 86, 1157 (1953)] and syringaresinol (where R 1 =R4=A, 2 3 R =R=R R nzl and m-1-1 in the general formula may be synthesized by the method of Freundenberg, et al.
(Chem. Ber., 88, 16(1955)].
The derivatives of the present invention or extracts containing them as main components may also be combined with antioxidants for use as effective components according to the present invention. The antioxidants available for use include natural antioxidants such as tocopherols, flavone derivatives, phyllodulcins, kojic acid, gallic acid derivatives, catechins, fukinolic acid, gossypol, pyrazine derivatives, sesamol, guaiacol, guaiac resin, p-couxnalic acid, nordihydroguaiaretic acid, sterols, terpenes, nucleic acid bases, carotenoids, etc.
and synthetic antioxidants such as butylhydroxyanisole (BHA), butylhydroxytoluene (BHT), monotertiarybutyihydroquinone (TBHQ), 4-hydroxymethyl-2, 6-ditertiarybutyiphenol (HU4BP), etc.
Tocopherols are particularly preferred from among these antioxidants, and examples of tocopherols include ct-tocopherol, B-tocopherol, y-tocopherol, 8-tocopherol, e-tocopherol, E-tocophero1, iq-tocopherol and tocopherol esters (tocopherol acetate, etc.). In addition, as :carotenoids there may be mentioned B-carotene, .canthaxanthin, astaxanthin, etc.
There are no particular restrictions on the :proportions of the derivative of the present invention and the antioxidant in combination, but the antioxidant is preferably present at between 0.001 parts by weight and 1000 parts by weight with respect to 1 part by weight 35 of the derivative of the present invention. A more preferred range is from 0.01 to 100 parts by weight, and an even more preferred range is from 0.029 to 40 parts byweight with respect to 1 part by weight of the derivative of the present invention.
The effective components of the present invention, namely the derivatives of the present invention alone or in combination with the antioxidants, is effective for the prevention or alleviation of allergy symptoms because they suppress the release of chemical mediators (histamine, LTB 4
LTC
4 etc.) by causing an increase of the levels of IgA which inhibits allergen absorption and of IgG which arrests reaction between allergens and IgE.
Among the allergy symptoms which are the object of the present invention there may be mentioned symptoms of allergic diseases such as atopic dermatitis, adolescent atopic dermatitis, hives, contact dermatitis, senile dermatosis, bronchial asthma, allergic rhinitis, pollenosis, ischemic diseases, cardial anaphylaxis, endotoxic shock, psoriasis, drug allergy, food allergy, insect allergy, and the like. According to the present invention, the alleviation of symptoms has a wide meaning, also including curing of the disorder.
For example, in the case of pollenosis, the effective components of the present invention, ~:.particularly the derivative of the present invention and the antioxidant, would be expected to bind to IgG distributed throughout the mucous membrane before pollen (allergens) absorbed at the surface of the nasal mucosa react with IgE attached to mast cells, thus inhibiting the reaction between the allergen and the IgE, and therefore no histamine is released from the mast cells ~.and the allergy symptoms are suppressed.
Food allergies are allergies provoked by daily ingested foods, causing in addition to symptoms in the digestive organs where the food first contacts (swelling of oral mucous membrane, itching sensation, irritability, vomiting, abdominal pain, diarrhea), also cutaneous symptoms (eczema, hives), respiratory symptoms (nasal allergy, bronchial asthma), urinary symptoms (increased urination frequency, nocturnal urination), nervous symptoms (migraine), and the like. Such allergens include eggs, milk, soybeans, peanuts, chocolate, wheat flour, marine products, spices, preservatives, coloring agents and other food additives, microorganisms, medicines, and the like. With bronchial asthmatic children there is first an outbreak of eczema due to food allergy, from which nasal allergy due to inhaled allergens then progresses to bronchial asthmia. Most important for avoiding outbreak of such food allergies is to avoid intake of the allergens, but this is not practical.
Use of the effective components of the present invention, particularly the derivatives of the present invention and the antioxidants, is also believed to exhibit an anti-allergic effect by causing an increase in the level of IgA antibody produced by the mesenteric lymph node, allowing it to adhere to the food (allergen) absorbed at the enteric rnucosa.
When the effective components of the present invention are used as drug products, their form of administration may be either oral or parenteral depending on convenience, such forms including injections, infusions, powders, granules, tablets, capsules, enteric coated tablets, lozenges enteric capsules, troche, mixture for internal use, suspensions, emulsions, syrups, liquid for external use, tomentations, nasal drops, ear drops, eye drops, inhalants, ointments, lotions, suppositories, etc. which may be used either alone or in combination depending on the symptoms.
These preparations may be prepared according to usual methods using, together with the active components, known adjuvants which are normally used in the field of dr-ug preparation, including excipients, binders, preservatives, stabilizers, disintegrators, lubricants, flavor correctors, and the like, depending on the 12 purpose. For example, when preparing injections, drug solubilizers such as non-ionic surfactants and the like may be used, and more specifically, a derivative of the present invention may be heated to dissolution in a nonionic surfactant such as an 80-fold volume of POE hydrogenated castor oil or POE sorbitan monooleate, with dilution with physiological saline to complete the preparation. Alternatively, appropriate isotonizing agents, stabilizers, preservatives and soothing agents may also be added if necessary.
In addition, external preparations may employ vaseline, paraffin, fats and oils, lanolin, macrogol, etc. as bases to prepare ointments, creams and the like by common methods. Also, the dosages will differ depending on the purpose of administration and conditions of the patient (sex, age, body weight, etc.), but normally for administration to adults, the total amount of the derivative of the present invention may be appropriately adjusted in the range of 1 mg to 10g per day, preferably 1 mg to 2g per day, and more preferably 1 mg to 200 mg per day in the case of oral administration, and in the range of 0.1 mg to lg per day, preferably 0.1 mg to 200 mg per day, and more preferably 0.1 mg to 100 mg per day in the case of parenteral administration.
Furthermore, when the derivatives of the present invention are administered together with antioxidants, especially tocopherols, the dosages of the derivatives of the present invention will differ depending on the Spurpose of administration and conditions of the patient 30 (sex, age, body weight, etc.), but normally for administration to adults, the total amount of the derivative of the present invention may be appropriately adjusted in the range of 0.1 mg to 2g per day, preferably 0.1 mg to 500 mg per day, and more preferably 0.1 mg to 100 mg per day in the case of oral administration, and in the range of 0.01 mg to 200 mg per day, preferably 0.01 mg to 50 mg per day, and more preferably 0.01 mg to 20 mg 13 per day in the case of parenteral administration, while the mixing ratio of the derivative of the present invention and the antioxidant may be appropriately adjusted in the range of 0.001 to 1000 parts by weight, preferably 0.01 to 100 parts by weight, and more preferably 0.029 to 40 parts by weight of the antioxidant to 1 part by weight of the derivative of the present invention. The use of the derivatives of the present invention with antioxidants, particularly tocopherols, is expected to provide a synergistic effect of prevention and alleviation of allergy symptoms.
The derivatives of the present invention are clearly superior from the point of view of safety, since they are compounds discovered from traditional foods, or related compounds. This is also clear from the fact that when sesamin was continuously administered (orally) to 7-weekold male IRC mice at 2.14 gfday/kg for 2 weeks, no abnormal symptoms were observed.
When the effective components of the present invention or are used as food products, they may be in the form of the above-mentioned drug preparations, or in the form of solid or liquid foods and popular foods, **:*including as bread, noodles, rice confectioneries (such as biscuits, cake, candy, chocolate, Japanese sweets); agricultural foods such as tofu and their processed products; fermented foods such as Japanese sake, medicinal alcoholic drinks, sweet sake (mirin), vinegar, soysauce and soypaste (miso); oil and fat foods such as dressings, mayonnaise, margarine, shortening and edible fat and oili livestock food products such as yog-urt, ham, bacon and sausage; marine foods such as steamed fish paste (kamaboko), boiled fish paste (hanpen), and fried fish paste; and beverages such as juices, soft drinks, sports drinks, alcoholic drinks, tea and the like.
Also, when used as health foods or functional foods, they may be in the form of the above-mentioned drug preparations or food products, but they may also be in -14 processed form, such as liquid foods, semi-digested nutrient foods, component nutrient foods or drinks to which have been added, for example, proteins (proteins from protein sources such as milk protein, soybean protein and egg albumin which have balanced amino acids and high nutritional value are most widely used, but decomposition products of these, egg-white oligopeptides, soybean hydrolysates, etc. and mixtures of amino acid monomers may also be used), saccharides, fats, trace elements, vitamins, emulsifiers or spices.
A food product of the present invention may be processed by a common method of production with addition of a prescribed amount of a derivative of the present invention or an extract which contains it as a main component, to a food which substantially contains no derivative of the present invention. The mixing amount thereof will depend on the form of the preparation or food and is not particularly restricted, but generally it is preferred to be from 0.001 to 50%. Also, it may be taken as a health food or functional food product for the prevention or alleviation of the above-mentioned allergy symptoms, and for the preparation of hospital food, a *derivative of the present invention or an extract which contains it as a main component may be added to a desired food which substantially contains no derivative of the present invention, and given to a patient in the form of a functional food product prepared on the spot, under the control by a direction according to doctors diet prescription.
According to the present invention, a food substantially containing no derivative of the present invention is a food which is not prepared from a starting material such as sesame, but foods prepared from sesame and the like are also included as foods substantially containing no derivatives of the present invention if the food products in their final form contain only a trace amount of a derivative of the present invention, with the content of the derivative of the present invention being less than 0.1 mg, and preferably 0.8 mg or less per daily portion of the food; or the total content of sesamin, sesaminol, episesamin, episesaminol, sesamolin, 2-(3,4methylenedioxyphenyl)-6-(3-methoxy-4-hydroxyphenyl)-3,7dioxabicyclo[3.3.0]octane, 2,6-bis-(3-methoxy-4hydroxyphenyl)-3,7-dioxabicyclo[3.3.0]octane or 2-(3,4mnethylenedioxyphenyl -6-(3-methoxy-4-hydroxyphenoxy)-3,7dioxabicyclo[3.3.0]octane being less than 0.1 mg, and preferably 0.8 mg or less per daily portion of the food.
The food products of the present invention are preferably taken orally at a total daily dosage of derivatives of the present invention in the range of 1 mg to 0lg, preferably 1 mg to 2g, and more preferably 1 mg to 200 mg as a rule, for the purpose of prevention or alleviation of allergy symptoms and health maintenance.
In addition, when a derivative of the present invention or an extract containing it as a main component is taken together with an antioxidant, particularly a tocopherol, as a rule, it is preferably taken orally, with the total daily dosage of the derivative of the present invention being in the range of 0.1 mg to 2g, preferably 0.1 mg to 500 mg, and more preferably 0.1 mg S. to 100 mg, and the mixing ratio of the derivative of the S. 25 present invention and the antioxidant being in the range of 0.001 to 1000 parts by weight, preferably 0.01 to 100 parts by weight, and more preferably 0.029 to 40 parts by weight of the antioxidant to 1 part by weight of the derivative of the present invention. The combined use of 30 a derivative of the present invention and an antioxidant, particularly a tocopherol, is expected to provide a synergistic effect of prevention and alleviation of allergy symptoms and health maintenance.
In cases where a derivative of the present invention 35 or an extract containing it as a main component is added S" to a food which substantially contains no derivative of the present invention but contains an antioxidant, 16 particularly a tocopherol, the derivative of the present invention or the extract containing it as a main component may be added so that the proportion of the derivative of the present invention and the antioxidant in the food product in its final form is in the range of 0.001 to 1000 parts by weight, preferably 0.01 to 100 parts by weight, and more preferably 0.029 to 40 parts by weight of the antioxidant to 1 part by weight of the derivative of the present invention. An antioxidant may be further added at this time, if necessary.
The present invention is more concretely described below with reference to the following examples.
EXAMPLES
Example 1 Experimental animals and diets Four groups of 4-week-old (average body weight: 96g) male Brown-Norway (BN) rats (from Seiwa Experimental Animals) were formed with 8 rats per group. One group was given normal diet comprising 20% casein, 5% corn oil, 5% cellulose, 3.5% mineral mixture (AIN-TM: American Institute of Nutrition), 1% vitamin mixture (AIN-TM), 0.2% choline bitartrate, 0.3% DL-methionine, 15% corn starch and 50% sucrose. The remaining 3 groups were given diet containing 0.5% sesamin or 0.5% a-tocopherol at the expense of sucrose, with further addition of sesamin and 0.5% a-tocopherol at the expense of sucrose.
The sesamin used was a mixture of sesamin and episesamin (sesamin: 55.2%, episesamin: 44.4%, purity: 99.6%) purified by the method described in Japanese Unexamined S 30 Patent Publication No. 3-27319. After 3 weeks of feeding, blood was taken from the abdominal aorta under diethyl ether anesthesia, and the lung and spleen were So excised.
Extraction and measurement of leukotriene C, S 35 The leukotriene C 4
(LTC
4 concentration in the lung tissue excised from the rats was assayed by 17 radioimmunoassay according to a common method.
The results are shown in Fig. I. As this graph clearly shows, LTC 4 was significantly lower with administration of both sesamin and tocopherol.
Analysis of C41%), CD8 by flow c tomet The proportions of CD4* and CD8 cells in the blood were measured by flow cytometry (FCM). The spleens excised from the rats were transferred to 5 ml dishes containing RPMI 1640 medium, the fat was removed from the spleens, both ends were cut off, and the remaining portions were cut into 3 or 4 pieces. These were transferred to dishes containing fresh RPMI 1640 medium and triturated with a glass slide, and cells including lymphocytes were collected.
A 4 ml portion of lymphocyte separating medium (LSM) was added to each group of cells and the mixtures centrifuged, and then the resulting lymphocyte layers were drawn out for separation and transferred to RPMI 1640 medium. To each of the cell suspensions there was added 10 ml of fetal bovine serum (FBS), and dilution was performed with this medium to prepare solutions of 1 x 106 cells/ml, which were poured into 10 ml dishes. To each 10 ml dish there was added 100 p. of lysine solution at increasing final concentrations of from 1 x 10" ng/ml to 10 ng/nil.
After 48 hours, a portion of each culture solution was taken for antibody measurement, and the remaining cell suspension was adequately pipetted and then transferred to a centrifuge tube containing 10 ml of RPMI bo 30 1640 medium and centrifuged at 1200 rpm for 5 minutes.
Each of the supernatants was discarded, 1.5 ml of RPMI 1640 was again added and the mixtures thoroughly pipetted, and 100 4I thereof was poured into microtubes.
After centrifugation the superhatants were discarded, 2 ml of RPMI 1640 medium was added to the precipitated lymphocytes, and the mixtures were -18 thoroughly pipetted, 1 ml each, into microtubes, and again centrifuged at 1200 rpm for 5 minutes. The supernatants were discarded, 100 Ali of 10% inactivated FBS-containing PBS (phosphate buffered saline) was added, 5 g1 each of anti-rat CD 4 -FITC-labelled antibody and anti-rat CDs-PE-labelled antibody were added, and the mixtures were allowed to stand on ice for 30 minutes (stirring every 10 minutes). In addition, 1 mil of inactivated PBS/PBS was added, the mixtures were centrifuged at 1200 rpm for 5 minutes, the supernatants were again discarded, and the same procedure was repeated. The supernatants were discarded, 0.5 ml each of 4% paraformaldehyde solution and PBS were added and the mixtures were thoroughly pipetted (immobilization of 1s lymphocytes). These procedures were performed for the lymphocytes at all of the concentrations of lysine. The following day, the immobilized lymphocytes were measured by flow cytometry (F'CM) to determine the proportions of CD4+ cells and CD8+ cells. The results are shown in Table 1.
Table 1 C::Group Cont. Ses Toc Ses Toc CtD4 41.1 33.4 32.6 37.9 2 .Oab Lto* 2 DS 9.6 ±0.6L 7.4 7.1 7.3 t0.2b CD4 4 /CD8 4 4.3 ±0.1a 4. 6 ±0 .21 4.6 5.2 ±0.4' :values: average SE tooCont.: Control (no addition) Ses: 0.5% sesamin-added **Toc: 0.5% tcpeo-de Ses Toc: 0.5% sesamin and 0.5% tocopherol-added Significant differences between different letters, a and b: P<0.05 CD4 Helper T cell CD8%: Suppressor T cell 19 As is clear from Table 1, the spleen lymphocyte helper T cell (CD4*) with an immunoreactive effect was significantly lower with addition of sesamin.
Measurement of serum IqM, IqA, IG and IqE concentrations by ELISA (Enzyme-linked Immunosorbent Assay) The above-mentioned blood taken from rat abdominal aorta was used.
The reagents used were 50 mM carbonate-buffered rinsing solution (0.05% Tween 20/PBS, Wako Pure Chemical Industry), a blocking agent (Yukijirushi Dairy), 0.2 M citrate buffer containing primary and secondary IgA, IgM and IgG (Mie Kagaku), ABTS solution, substrate solution, reaction suspending solution, etc. The primary antibodies of IgM, IgA and IgG were diluted 1000-fold with 50 mM carbonate buffer (pH poured into a 96well plate at 100 gl in each well, and allowed to stand at 37 0 C for 1 hour.
After the plate was rinsed 3 or 4 times with rinsing solution, 300 L of 4-fold diluted Block Ace was poured into each well and allowed to stand at 37 0 C for I hour for blocking. After rinsing the plate 3 or 4 times with rinsing solution, 50 l of culture supernatant containing IgM, IgA and IgG was added to each well and allowed to 25 stand at 37 0 C for 1 hour for reaction. After rinsing the plate 3 or 4 times with rinsing solution, the enzymelabelled anti-IgM, IgA and IgG secondary antibodies were poured into the 96-well plate at 100 gL per well and allowed to stand at 37°C for 1 hour.
The plate was further rinsed 3 or 4 times with *rinsing solution, and then the substrate solution was added to the 96-well plate at 100 VL per well, and after reaction at 37 0 C for 5-15 minutes, the reaction suspending solution was added at 100 pL per well, and an o 35 ELISA microplate spectrophotometer was used to measure the absorbance of each well at 415 nm. IgM, IgA and IgG 20 standard solutions were added to the corresponding IgM, IgA and IgG culture supernatants, and the amounts of IgM, IgA and IgG in each culture supernatant were assayed from their primary regression lines.
The method of measuring the IgE concentration was almost the same as the method described above for measuring the IgM, IgA and IgG antibody concentrations, except that the abidin-biotin method was used in which enzyme-labelled abidin is added after 100 pL of biotinlabelled anti-IgE antibody is poured into each well of the plate. The plate was allowed to stand at 37°C for minutes. After rinsing 3 or 4 times, the substrate solution and reaction suspending solution were each added, and the IgE content was measured in the same manner as described above.
The results are shown in Fig. 2. In the group given a-tocopherol (a-Toc), the level of the allergen absorption-inhibiting factor IgA was significantly higher, while in the group given sesamin and a-tocopherol 20 (Ses a-Toc), the level of IgE, which plays a major role in Type I allergy, was significantly lower. These results suggest that the combined use of sesamin and cztocopherol has an anti-allergic action.
Discussion The production of the allergy-causing chemical mediator LTC4 was lower in the a-Toc group and Ses a- Toc group, but was higher in the sesamin (Ses) group.
Also, regarding the production of another allergy-causing chemical mediator PGE2, a tendency toward reduction was observed in the Ses and a-Toc groups, but there was an increase in the Ses a-Toc group. These results show that sesamin and a-tocopherol have different action sites, but both have suppressing effects against allergic reactions. In addition, it was confirmed that simultaneous administration of sesamin and a-tocopherol results in a synergistic effect of the two. It is indicated that the effective components of the present 21 invention, sesamin or sesamin and a-tocopherol, do not act at a single site of immunoreactions, but rather control immunoreactions by controlling more than one reaction. The use of such a combination of allergysuppressing factors is believed to attenuate allergic responses in allergy patients, and prevent progression of healthy persons to allergic constitutions.
Example 2.
Six groups of 4-week-old (average body weight: 96g) male Brown-Norway (BN) rats were formed with 8 rats per group. One group was given normal diet comprising casein, 5% corn oil, 5% cellulose, 3.5% mineral mixture (AIN-TM), 1% vitamin mixture (AIN-TM), 0.2% choline bitartrate, 0.3% DL-methionine, 15% corn starch and sucrose. The remaining 5 groups were given diets respectively containing, at the expense of sucrose, sesaminol prepared from crude sesame oil (compound A), sesamolin prepared from crude/purified sesame oil (compound or 2-(3,4-methylenedioxyphenyl)-6-(3- 20 methoxy-4-hydroxyphenyl)-3,7-dioxabicyclo[3.3.0]octane .(compound 2,6-bis-(3-methoxy-4-hydroxyphenyl)-3,7dioxabicyclo[3.3.0]octane (compound D) or 2-(3,4- Smethylenedioxyphenyl)-6-(3-methoxy-4-hydroxyphenoxy)-3,7- •dioxabicyclo[3.3.0]octane (compound E) prepared by acetone extraction of sesame seeds, the preparation being according to a method present under patent application (Japanese Unexamined Patent Publication No. 1-243992), with further addition of 0.5% a-tocopherol. After 3 weeks, the leukotriene C4 (LTC.) concentrations in the lung were examined according to Example 1. LTC 4 production in the lung in the normal diet group was 62.7 ±3.9 whereas in the groups given diet containing compounds A, B, C, D and E with a-tocopherol, it was significantly lower at 32.1 34.4 40.2 ±3.8, 44.5 ±3.4 and 39.7 respectively.
Example 3.
22 Experimental animals and diets Four groups of 4-week-old male (average body weight: 147g) Sprague-Dawley (SD) rats (Seiwa Experimental Animals) were formed with 6 rats per group. One group was given normal diet comprising 20% casein, 5% corn oil, cellulose, 3.5% mineral mixture (AIN-TM: American Institute of Nutrition), 1% vitamin mixture (AIN-TM), 0.2% choline bitartrate, 0.3% DL-methionine, 15% corn starch and 50% sucrose. The remaining 3 groups were given diets containing 0.5% sesamin or 0.5% a-tocopherol at the expense of sucrose, with further addition of sesamin and 0.5% a-tocopherol at the expense of sucrose.
The sesamin used was the same as used in Example 1.
After 3 weeks of feeding, blood was taken from the abdominal aorta under diethyl ether anesthesia, and the lung and spleen were excised.
The leukotriene B4 (LTB 4 and leukotriene
C
4
(LTC
4 concentrations in the lung and spleen tissues excised from the rats were assayed by radioimmunoassay according 20 to a usual method. In addition, 1.5 ml of plasma was placed in a centrifuge tube containing 1 ml of 1 N HCIO and mixed therewith, and then centrifuged (3000 rpm, minutes), and the histamine was extracted and assayed according to a usual method.
The results are shown in Fig. 3. As is clear from these graphs, the leukotriene B 4
(LTB
4 concentration in the spleen tissue and the histamine concentration in the plasma were lower with administration of sesamin and tocopherol, and were even more significantly lower with administration of both. In addition, the leukotriene C 4 (LTC) concentration in the lung tissue was significantly lower in a synergistic manner by administration of both sesamin and tocopherol. Thus, there were significantly lower levels of allergy-related chemical mediators with administration of sesamin alone or a combination of sesamin and tocopherol.
23 For measurement of the mesenteric lymph node immunoglobulin concentration, mesenteric lymph node was excised and the lymphocytes were squeezed out into RPMI 1640 medium (Nissui Pharmaceutical and after incubating the cells at 37 0 C for 30 minutes to remove the fibroblasts, 5 ml of the cell suspension was layered on 4 ml of Lympholyte-Rat (Cedarlane, Canada) and centrifuged (1500 x g, 30 min). The lymphocyte band at the interface was recovered, and the cells were rinsed three times with the RPMI 1640 medium. The lymphocytes were cultured in a fetal bovine serum (FBS, Intergen Co., U.S.A.)/RPMI 1640 medium. The MLN lymphocytes were adjusted to 2 x 106 cells/ml and incubated at 37 0 C for 6 hours, after which the concentrations of IgE, IgA, IgM and IgG were measured by the enzyme-linked immunosorbent assay
(ELISA).
The results are shown in Table 2. The concentration of the anti-allergic IgA was significantly higher with administration of sesamin. Furthermore, The S: 20 concentration of IgG which inhibits reaction between allergens and IgE antibody was significantly higher in a synergistic manner with administration of both sesamin :and tocopherol.
As shown above, sesamin alone or a combination of 25 sesamin and tocopherol may be used to prevent or improve allergy symptoms.
*o *o 24 r Table 2 Influence of sesamin and tocopherol on immunoglobulin concentration in mesenteric lymph node lymphocytes Group Concentration (ng/g) IgA IgG IgM IgE addontono 27.4 ±1.3a 4.7 10.34 0.7 1.9 ±1.1 Sesamin-added 61.8 ±3.1 4.6 ±0.2 n.d. 0.2 ±0.1 ocophe 30.1 ±1.0 7.3 ±0.9 b 1.7 0.5 ±0.2 Sesamin- and tocopherol- 46.9 ±0.8r 14.8 4.1 1.7 ±0.4 added Values: Average ±SE Significant differences between different letters, a, b and c: P<0.05 Not detected Example 4.
To 100g of butter fat from which the buttermilk had been removed by the stirring operation (churning) during the butter manufacturing process, there were added 1.2g of a mixture of sesamin and episesamin (sesamin: 51.3%, episesamin: 47.8%) and 1.2g of tocopherol acetate, and the kneading operation (working) was carried out to a homogeneous composition to obtain butter containing effective components of the present invention, which had an effect of preventing or improving allergy symptoms.
Example A 0.5g portion of the effective components of the present invention was mixed with 20.5g of silicic anhydride, and then 79g of corn starch was added prior to further mixing. A 100 ml portion of a hydroxypropylcellulose/ethanol solution was added to the mixture which was then heated, extruded and dried by 25 usual methods to obtain granules.
Example 6.
A 20g portion of silicic anhydride was mixed with of a mixture of sesamin and episesamin (sesamn: 51.3%, episesamin: 47.8%) and 0.5g of tocopherol acetate, and then lOg of microcrystalline cellulose, 3.Og of magnesium stearate and 60g of lactose were added and mixed therewith, and the mixture was tabletted using a single-shot slug tabletting machine to make tablets with a diameter of 7 mm and a weight of 100 mg.
Example 7.
A 2.5g portion of the effective components of the present invention was dissolved at 122*C in 200g of the non-ionic surfactant TO-10M (Nikko Chemicals), and 4.7975 liters of physiological saline sterilized by heating at was added and thoroughly mixed therewith, after which the mixture was distributed into aseptic vials which were sealed to prepare injections.
Example 8.
o Water was added to 100 parts by weight of gelatin and 35 parts by weight of glycerine food additive, which were dissolved therein at 50 to 60 0 C to prepare a gelatin membrane with a viscosity of 20,000 cps. Then, 95.1 wheat germ oil, 2.9% vitamin E oil and 2% sesamin were mixed to prepare the contents. These were used for capsule molding and drying by usual methods, to prepare soft capsules containing 180 mg of the contents per **capsule. Each capsule contained 3.6 mg of sesamin and 2.34 mg of a-tocopherol.
Clinical Example 1 Atopic dermatitis patients were orally administered one of the tablets prepared in Example 6 three times a day at morning, noon and night (total per tablet dosage of dioxabicyclo[3.3.0]octane derivative and antioxidant: 12.4 mg) for a period of 8 weeks, and the efficacy thereof was evaluated. As a result, in 3 of the atopic dermatitis patients, the present invention was 26 judged to be somewhat effective, effective or very effective.
Clinical Example 2 Atopic rhinitis patients were orally administered one of the capsules prepared in Example 8 three times a day at morning, noon and night (total per capsule dosage of dioxabicyclo[3.3.0]octane derivative and antioxidant: 17.82 mg) for a period of 8 weeks, and the efficacy thereof was evaluated. As a result, in 3 of the atopic rhinitis patients, the present invention was judged to be somewhat effective, effective or very effective.
Clinical Example 3 Pollenosis patients were orally administered one of the capsules prepared in Example 8 three times a day at morning, noon and night (total per capsule dosage of dioxabicyclo[3.3.0]octane derivative and antioxidant: 17.82 mg) for a period of 8 weeks, and the efficacy thereof was evaluated. As a result, in 2 of the 20 pollenosis patients, the present invention was judged to be somewhat effective, effective or very effective.
*o oo* *o *o *o 27 THE CLAIMS DEFINING THE INVENTION ARE AS FOLLOWS: 1. A method for the prevention or alleviation of allergy symptoms, comprising administering to a person in need of such prevention or alleviation, an effective amount to prevent or alleviate allergy symptoms of a dioxabicyclo[3.3.0]octane derivative represented by the following general formula R0O
OR
2 0
OR^
SRsO (OR 6 Swherein R 1
R
2
R
3
R
4
R
5 and R 6 each independently represent a hydrogen atom or alkyl group of 1 3 carbon atoms, or R 1 S" 'and R 2 and/or R and R 5 together represent a methylene or ethylene group, and n, m and 1 represent 0 or 1, and an antioxidant.
2. The method for the prevention or alleviation of allergy symptoms according to claim 1, wherein the compound of the formula and the antioxidant are administered in the form of a food or drink.
3. The method for the prevention or alleviation of allergy symptoms according to claim 2, wherein said food or drink is a health food or functional food.
4. The method for the prevention or alleviation of allergy symptoms according to any one of claims 1 to 3, wherein said antioxidant is tocopherol.
The method for the prevention or alleviation of allergy symptoms according to claim 1, wherein the allergy
Claims (4)
- 6. The method for the prevention or alleviation of allergy symptoms according to claim 1, wherein the allergy symptoms are associated with an allergy selected from the group consisting of drug allergy, food allergy and insect allergy.
- 7. The method for the prevention or alleviation of allergy symptoms according to claim 6, wherein the allergy symptoms are associated with a food allergy. S
- 8. The method for the prevention or alleviation of allergy symptoms according to claim 1, wherein the dioxabicyclo[33.3.0octane derivative and the antioxidant are administered orally or parenterally to a person in need of such prevention or alleviation.
- 9. The method for the prevention or alleviation of allergy symptoms according to any one of claims 1 to 8, wherein said dixabicyclo[3.3.0]octane derivative administered is at least one of sesamin, sesaminol, episesamin, episesaminol, sesamolin, 2 4 -methylenedioxyphenyl)-6-(3- methoxy-4-hydroxyphenyl)-3,7-dioxabicyclo[3.3.0]octane, 2,6- bis-(3-methoxy-4-hydroxyphenyl)-3,7-dioxabicyclo[3.3.0]octane or 2 3 4 -methylenedioxyphenyl)-6-(3-methoxy-4- hydroxyphenoxy)-3,7-dioxabicyclo[3.3.0]octane. Dated this 1st day of February 1999 SUNTORY LIMITED By their Patent Attorneys GRIFFITH HACK Fellows Institute of Patent and Trade Mark Attorneys of Australia AGENT FOR PREVENTION OR ALLEVIATION OF ALLERGY SYMPTOMS ABSTRACT OF DISCLOSURE An agent for the prevention or alleviation of allergy symptoms contains as an effective component a dioxabycyclo[3.3.0]octane derivative represented by the following general formula OR' OR' 0 1 2 3 4 5 6 or 1. 25 An agent for the prevention or alleviation of dioxabicyclo3.3.0]octane derivative. atoms, or R' and R2 and/or R4 and RS together represent a methylene or ethylene group, and n, m and 1 represent 0 or i. 25 An agent for the prevention or alleviation of allergy symptoms also contains as an effective component an antioxidant in addition to the dioxabicyclo[3.3.0]octane derivative. o
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP6-098798 | 1994-05-12 | ||
| JP9879894 | 1994-05-12 | ||
| JP10420995A JP3818680B2 (en) | 1994-05-12 | 1995-04-27 | Preventive or ameliorating agent for allergic symptoms |
| JP7-104209 | 1995-04-27 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| AU1799495A AU1799495A (en) | 1995-11-23 |
| AU703327B2 true AU703327B2 (en) | 1999-03-25 |
| AU703327C AU703327C (en) | 2000-09-28 |
Family
ID=
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0387000A2 (en) * | 1989-03-07 | 1990-09-12 | Suntory Limited | Medicament for the treatment of thrombus, inflammation and high blood pressure |
| EP0409654A2 (en) * | 1989-07-21 | 1991-01-23 | Suntory Limited | Liver function improver |
| EP0519673A1 (en) * | 1991-06-15 | 1992-12-23 | Suntory Limited | Composition containing dioxabicyclo[3.3.0]octane derivative |
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0387000A2 (en) * | 1989-03-07 | 1990-09-12 | Suntory Limited | Medicament for the treatment of thrombus, inflammation and high blood pressure |
| EP0409654A2 (en) * | 1989-07-21 | 1991-01-23 | Suntory Limited | Liver function improver |
| EP0519673A1 (en) * | 1991-06-15 | 1992-12-23 | Suntory Limited | Composition containing dioxabicyclo[3.3.0]octane derivative |
Also Published As
| Publication number | Publication date |
|---|---|
| DK0681788T3 (en) | 2004-12-06 |
| DE69533298T2 (en) | 2004-12-30 |
| SG38841A1 (en) | 1997-04-17 |
| CA2149170C (en) | 2006-12-19 |
| US5922760A (en) | 1999-07-13 |
| CA2149170A1 (en) | 1995-11-13 |
| AU1799495A (en) | 1995-11-23 |
| EP0681788B1 (en) | 2004-07-28 |
| SI0681788T1 (en) | 2004-12-31 |
| ATE271786T1 (en) | 2004-08-15 |
| DE69533298D1 (en) | 2004-09-02 |
| PT681788E (en) | 2004-11-30 |
| ES2220919T3 (en) | 2004-12-16 |
| KR950031067A (en) | 1995-12-18 |
| JP3818680B2 (en) | 2006-09-06 |
| JPH0826989A (en) | 1996-01-30 |
| EP0681788A2 (en) | 1995-11-15 |
| KR20070108291A (en) | 2007-11-09 |
| EP0681788A3 (en) | 1998-01-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP3512196B2 (en) | Food composition comprising a balance regulator for omega-6 and omega-3 unsaturated fatty acids | |
| US5180588A (en) | Liver function improver | |
| KR100399671B1 (en) | Prevention or amelioration of hypertension or a medical symptom thereof | |
| CA2593423A1 (en) | Therapeutic uses of tomato extracts | |
| EP3590356A1 (en) | Composition for controlling and reducing blood cholesterol levels | |
| JP2008297209A (en) | Lipid metabolism-improving composition | |
| US5211953A (en) | Liver function improver | |
| CA2053820C (en) | Method of inhibiting metabolism of cholesterol | |
| US20140005144A1 (en) | Novel leukotriene receptor antagonist | |
| EP0519673A1 (en) | Composition containing dioxabicyclo[3.3.0]octane derivative | |
| KR101965061B1 (en) | Composition for prevention or treatment of metabolic disorder comprising peanut sprout extracts and fractions thereof | |
| JPH08225453A (en) | Lipoprotein (a) depressor, cholesterol depressor and medicine containing the same | |
| US7767236B2 (en) | Plant seed extract composition and process for producing the same | |
| KR100966719B1 (en) | Composition comprising Orostachys japonicus extract for inhibiting obesity and for preventing or treating hyperlipidemia | |
| EP0681788B1 (en) | Dioxabicyclo[3.3.0] octane derivatives, e.g. sesamin etc., for prevention or alleviation of allergy symptoms | |
| KR100964906B1 (en) | Pharmaceutical composition for treating or preventing an inflammatory disease comprising licarin E | |
| KR100926454B1 (en) | The composition comprising the extracts, fractions and the isolated compounds of Rhus verniciflua for prevention and treatment of diabetic complications | |
| JPH07149628A (en) | Improver for lipid metabolism | |
| KR20060060309A (en) | Composition comprising extract of phellinus sp. pl3 or phellinsin a isolated from the same as an effective component for prevention and treatment of cardiac circuit disease | |
| KR20110076053A (en) | Composition for preventing and treating metabolic disease comprising extract of thymus capitatus or extract of satureja hortensis as an active ingredient | |
| KR20110128068A (en) | Hopea odrata extact, pharmaceutical composition and healthy functional food | |
| KR20090017824A (en) | Composition comprising niga-ichigoside f1 for inhibiting obesity, and preventing or treating diabetes mellitus and hyperlipidemia | |
| KR20150074450A (en) | Composition for treating and improving fatty liver and hyperlipidemia comprising extract of olive as an active ingredient |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| DA2 | Applications for amendment section 104 | ||
| DA3 | Amendments made section 104 |
Free format text: 15071999 |
|
| DA3 | Amendments made section 104 |
Free format text: THE NATURE OF THE AMENDMENT IS AS WAS NOTIFIED IN THE OFFICIAL JOURNAL DATED 20000203 |